Source: Tech – South China Morning PostA Chinese biotech firm that soared more than 4,500 per cent in the three months since its Hong Kong debut, has stoked fears of a speculative bubble in China healthcare stocks.
Shares of TransThera Sciences soared as much as 64 per cent to HK$679.50 in Hong Kong trading on Tuesday, after pricing at just HK$13.15 in late June – a more than 50-fold gain that has made it the top performer on the Hang Seng Healthcare Index this year.
TransThera noted the “unusual movements” in its share price in an…Read More